An alternate-day corticosteroid regimen for pemphigus vulgaris. A 13-year prospective study

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 10, 2007, Pages 1386-1391

  Chaidemenos, G Ch ^a   Mourellou, O ^a   Koussidou, T ^a   Tsatsou, F ^b  

^a State Hospital for Skin and Venereal Diseases   (Greece)

^b DESSAU MEDICAL CENTER   (Germany)

Author keywords

Alternate day; Azathioprine; Immunosuppressants; Lever's mini treatment; Pemphigus vulgaris; Prednisone

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HEMOPOIETIC GROWTH FACTOR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; BONE MARROW DEPRESSION; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORNING DOSAGE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; TOXIC HEPATITIS; TUBERCULOSIS;

ADMINISTRATION, ORAL; ADULT; AGED; AZATHIOPRINE; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PEMPHIGUS; PREDNISONE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 35649007331     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02286.x     Document Type: Article

References (23)

1. Scully C, Paes de Almeida O, Porter SR, Gilkes JJH. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol 1999; 140: 84-89.
2. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996; 132: 203-212.
3. Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey 0f 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol 1988; 68: 413-421.
4. Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. A 5-year study. Int J Dermatol 1990; 29: 363-367.
5. Fernandes NC, Perez M. Treatment of pemphigus vulgaris and pemphigus foliaceus: Experience with 71 patients over a 20 year period. Rev Inst Med Trop Sao Paulo 2001; 43: 33-36.
6. Minouri D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt G. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003; 49: 1059-1062.
7. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: Therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol 1977; 113: 1236-1241.
8. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol 1984; 120: 44-47.
9. Mourellou O, Chaidemenos GC, Koussidou Th, Kapetis E. The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period. Br J Dermatol 1995; 133: 83-87.
10. Benoit Corven C, Carvalho P, Prost C et al. Traitement du pemphigus vulgaire par le protocole 'Lever faible'. Ann Dermatol Venereol 2003; 130: 13-15.
11. Kanitakis C, Chrysomallis F, Ktenides MA, Haidemenos G. Etude en peau saine de l'immunofluorescence directe dans le pemphigus vulgaire. Ann Dermatol Venereol 1978; 105: 649-651.
12. Chryssomallis F, Dimitriades A, Chaidemenos G, Panagiotides D, Karakatsanis G. Steroid-pulse therapy in pemphigus vulgaris. Long term follow-up. Int J Dermatol 1995; 34: 438-442.
13. Chaidemenos G, Mourellou O, Butli F et al. Factors promoting a successful and cost-effective management of pemphigus vulgaris with high-dose I.V. IgG. Int J Immunopathol Pharmacol, Section Dermatol 2006; 13: 465-469.
14. Bystryn J-C, Rudolph JL. IVIg treatment of pemphigus: How it works and how to use it. J Invest Dermatol 2005; 125: 1093-1098.
15. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol 1987; 16: 527-533.
16. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: The past, the present, and the future. J Am Acad Dermatol 2006; 55: 369-389.
17. Gallant C, Kenny P. Oral glucocorticoids and their complications. J Am Acad Dermatol 1986; 14: 161-177.
18. Mahajan VK, Sharma NL, Sharma RC, Garg G. Twelve-year clinico-therapeutic experience in pemphigus: A retrospective study of 54 cases. Int J Dermatol 2005; 44: 821-827.
19. Ackerman G, Nohan C. Adrenal cortical responsiveness after alternate-day corticosteroid therapy. N Engl J Med 1968; 278: 405-409.
20. Mutasim DF. Management of autoimmune bullous diseases: Pharmacology and therapeutics. J Am Acad Dermatol 2004; 51: 859-877.
21. Harman KE, Albert S, Black MM; British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926-937.
22. Brenner S, Bar-Nathan EA. Pemphigus vulgaris triggered by emotional stress. J Am Acad Dermatol 1984; 11: 524-525.
23. Brenner S, Tur F, Shapiro J et al. Pemphigus vulgaris: Environmental factors. Occupational, behavioural, medical, and qualitative food frequency questionnaire. Int J Dermatol 2001; 40: 562-569.